240 related articles for article (PubMed ID: 35853017)
21. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
22. 68Ga-PSMA PET/CT in Patients With Biochemical Recurrence of Prostate Cancer: A Prospective, 2-Center Study.
Zacho HD; Nielsen JB; Dettmann K; Haberkorn U; Langkilde NC; Jensen JB; Petersen LJ
Clin Nucl Med; 2018 Aug; 43(8):579-585. PubMed ID: 29916917
[TBL] [Abstract][Full Text] [Related]
23. How accurate is
Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
[TBL] [Abstract][Full Text] [Related]
24. Primary lymph-node staging with
Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
[TBL] [Abstract][Full Text] [Related]
25. The Diagnostic Performance of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients with Early Recurrence after Definitive Therapy with a PSA <10 ng/ml.
Lengana T; Lawal I; Janse Van Rensburg C; Mokoala K; Moshokoa E; Mazibuko S; Van de Wiele C; Maes A; Vorster M; Sathekge MM
Nuklearmedizin; 2022 Apr; 61(2):120-129. PubMed ID: 35421900
[TBL] [Abstract][Full Text] [Related]
26.
Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
[TBL] [Abstract][Full Text] [Related]
27. Prospective Comparison of
Duan H; Song H; Davidzon GA; Moradi F; Liang T; Loening A; Vasanawala S; Iagaru A
J Nucl Med; 2024 Jun; 65(6):897-903. PubMed ID: 38664016
[TBL] [Abstract][Full Text] [Related]
28.
Farolfi A; Ceci F; Castellucci P; Graziani T; Siepe G; Lambertini A; Schiavina R; Lodi F; Morganti AG; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):11-19. PubMed ID: 29905907
[TBL] [Abstract][Full Text] [Related]
29. Prospective intra-individual blinded comparison of [
Pattison DA; Debowski M; Gulhane B; Arnfield EG; Pelecanos AM; Garcia PL; Latter MJ; Lin CY; Roberts MJ; Ramsay SC; Thomas PA
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):763-776. PubMed ID: 34383089
[TBL] [Abstract][Full Text] [Related]
30. Matched-Pair Comparison of
Rauscher I; Krönke M; König M; Gafita A; Maurer T; Horn T; Schiller K; Weber W; Eiber M
J Nucl Med; 2020 Jan; 61(1):51-57. PubMed ID: 31253741
[No Abstract] [Full Text] [Related]
31. 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
Barbaud M; Frindel M; Ferrer L; Le Thiec M; Rusu D; Rauscher A; Maucherat B; Baumgartner P; Fleury V; Colombié M; Thierry-Morel A; Kraeber-Bodéré F; Campion L; Rousseau C
Prostate; 2019 Apr; 79(5):454-461. PubMed ID: 30549066
[TBL] [Abstract][Full Text] [Related]
32. [
Green MA; Hutchins GD; Bahler CD; Tann M; Mathias CJ; Territo W; Sims J; Polson H; Alexoff D; Eckelman WC; Kung HF; Fletcher JW
Mol Imaging Biol; 2020 Jun; 22(3):752-763. PubMed ID: 31429050
[TBL] [Abstract][Full Text] [Related]
33. Head-to-Head Comparison of
Kuten J; Fahoum I; Savin Z; Shamni O; Gitstein G; Hershkovitz D; Mabjeesh NJ; Yossepowitch O; Mishani E; Even-Sapir E
J Nucl Med; 2020 Apr; 61(4):527-532. PubMed ID: 31562225
[No Abstract] [Full Text] [Related]
34.
Pfister D; Haidl F; Nestler T; Verburg F; Schmidt M; Wittersheim M; Steib F; Heidenreich A
BJU Int; 2020 Dec; 126(6):679-683. PubMed ID: 32531840
[TBL] [Abstract][Full Text] [Related]
35. Prospective comparison of whole-body MRI and
Sawicki LM; Kirchner J; Buddensieck C; Antke C; Ullrich T; Schimmöller L; Boos J; Schleich C; Schaarschmidt BM; Buchbender C; Heusch P; Rabenalt R; Albers P; Antoch G; Müller HW; Hautzel H
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1542-1550. PubMed ID: 30879122
[TBL] [Abstract][Full Text] [Related]
36. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ
BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
[TBL] [Abstract][Full Text] [Related]
37. PSA-stratified detection rates for [
Derlin T; Schmuck S; Juhl C; Zörgiebel J; Schneefeld SM; Walte ACA; Hueper K; von Klot CA; Henkenberens C; Christiansen H; Thackeray JT; Ross TL; Bengel FM
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):913-922. PubMed ID: 29308527
[TBL] [Abstract][Full Text] [Related]
38.
Hamed MAG; Basha MAA; Ahmed H; Obaya AA; Afifi AHM; Abdelbary EH
Acad Radiol; 2019 Apr; 26(4):450-460. PubMed ID: 29935970
[TBL] [Abstract][Full Text] [Related]
39. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
van Leeuwen PJ; Stricker P; Hruby G; Kneebone A; Ting F; Thompson B; Nguyen Q; Ho B; Emmett L
BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282
[TBL] [Abstract][Full Text] [Related]
40. Interobserver variability, detection rate, and lesion patterns of
Miksch J; Bottke D; Krohn T; Thamm R; Bartkowiak D; Solbach C; Bolenz C; Beer M; Wiegel T; Beer AJ; Prasad V
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2339-2347. PubMed ID: 32157427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
